Oncorus Inc. (ONCR)
Company Description
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients.
The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers.
It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus.
The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors.
Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| IPO Date | Oct 2, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 64 |
| CEO | Craig R. Jalbert CIRA |
Contact Details
Address: 50 Hampshire Street Cambridge, Massachusetts United States | |
| Website | https://www.oncorus.com |
Stock Details
| Ticker Symbol | ONCR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001671818 |
| CUSIP Number | 68236R103 |
| ISIN Number | US68236R1032 |
| Employer ID | 47-3779757 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Brian J. Shea | Pres, Interim Chief Executive Officer, Gen. Counsel & Corporation Sec. |
| Craig R. Jalbert CIRA | Chief Executive Officer, President, Chief Financial Officer, Treasurer, Secretary & Director |
| Alexander Nolte | Interim Chief Financial Officer, Principal Accounting Officer & Treasurer |
| Richard J. Wanstall M.B.A. | Chief Financial Officer, Chief Accounting Officer & Treasurer |
| Stephen W. Harbin | Chief Operating Officer & Chief of Staff |
| Brian J. Shea | Director of Legal Counsel & Corporation Sec. |
| Chris German | Controller |
| Dr. John Mayer Goldberg M.D. | Chief Medical Officer |
| Dr. Mitchell H. Finer Ph.D. | Non-Executive Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 07, 2023 | DEFA14A | Filing |
| Aug 03, 2023 | 15-12G | Filing |
| Aug 03, 2023 | DEFA14A | Filing |
| Aug 03, 2023 | 8-K | Current Report |
| Jul 28, 2023 | DEFA14A | Filing |
| Jul 28, 2023 | 8-K | Current Report |
| Jul 19, 2023 | S-8 POS | Filing |
| Jul 19, 2023 | S-8 POS | Filing |
| Jul 19, 2023 | S-8 POS | Filing |
| Jul 19, 2023 | S-8 POS | Filing |